Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Paul Gavine"'
Autor:
Elaine Lai-Han Leung, Run-Ze Li, Xing-Xing Fan, Lily Yan Wang, Yan Wang, Zebo Jiang, Jumin Huang, Hu-Dan Pan, Yue Fan, Hongmei Xu, Feng Wang, Haopeng Rui, Piu Wong, Hermi Sumatoh, Michael Fehlings, Alessandra Nardin, Paul Gavine, Longen Zhou, Yabing Cao, Liang Liu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung
Externí odkaz:
https://doaj.org/article/c845ab00de49468c83ac80f41f9fb0d6
Data from Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Purpose: Extensive correlative studies in human prostate cancer as well as studies in vitro and in mouse models indicate that fibroblast growth factor receptor (FGFR) signaling plays an important role in prostate cancer progression. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f3eefe3a20a257805aa44f6fd08cbe
https://doi.org/10.1158/1078-0432.c.6520704.v1
https://doi.org/10.1158/1078-0432.c.6520704.v1
PDF file, 34KB, Primer sequences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1adaface21d1e1f73037471a1c272e90
https://doi.org/10.1158/1078-0432.22446261
https://doi.org/10.1158/1078-0432.22446261
PDF file, 188KB, AZ8010 inhibits VCaP proliferation and increases apoptosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90414f0beae08c240a4c802616e9f583
https://doi.org/10.1158/1078-0432.22446273
https://doi.org/10.1158/1078-0432.22446273
PDF file, 223KB, Ki67 and CD31 immunohistochemistry and TUNEL of VCaP tumors from mice treated with AZ8010 or vehicle only.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d94294241439394387c1dbfb24553b
https://doi.org/10.1158/1078-0432.22446270
https://doi.org/10.1158/1078-0432.22446270
PDF file, 954KB, Treatment with AZ8010 does not inhibit AKT phosphorylation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a030f0247cfb7ae95ffb225df8bd120
https://doi.org/10.1158/1078-0432.22446267.v1
https://doi.org/10.1158/1078-0432.22446267.v1
Autor:
Lars-Eric Fielmich, Annemarie Buijs, Daniele Mori, Bas Viergever, Nihed Draoui, Anna Schepers, Mariana M. Costa e Silva, Mathijs Scholtus, Tokameh Mahmoudi, Tahlita Zuiverloon, Merel Derksen, Paul Gavine, Sylvia F. Boj, Richard Meijer, Onno Kranenburg, Janine Arts, Robert Vries
Publikováno v:
Cancer Research. 83:189-189
Conventional models for preclinical drug screening offer poor predictive value for patient response, causing high attrition rates of new agents in the clinic. HUB’s proprietary Patient-Derived Organoid (PDO) Technology enables long-term expansion o
Autor:
Run-Ze Li, Yue Fan, Haopeng Rui, Longen Zhou, Paul Gavine, Liang Liu, Hongmei Xu, Yabing Cao, Michael G. Fehlings, Ze-Bo Jiang, Piu Wong, Xing-Xing Fan, Alessandra Nardin, Hu-Dan Pan, Hermi Sumatoh, Elaine Leung, Yan Wang, Lily Yan Wang, Ju-Min Huang
The response to immunotherapy could be better predicted by using a wide set of biomarkers, including serum tumor markers; however, robust immune markers associated with efficacy have yet to be validated. In this study, changes in immune cell subsets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad2e68f4b7dfe4f532452ae3f1006291
https://doi.org/10.21203/rs.3.rs-863654/v1
https://doi.org/10.21203/rs.3.rs-863654/v1
Autor:
Paul Gavine, Tu Wangyang, Dai Xuedong, Ricardo Attar, Yingtao Liu, Jing Zhang, Wenqian Wang, Liu Qian, Xu Yanping, Linglong Kong, Fu Liqiang, Ulrike Philippar, Xiaotao Wang, Na Cheng, James P. Edwards, Bin Shen, Jennifer Yang, Jennifer D. Venable, Mingxuan Xia, Xin Cai, Tianyuan Zhou
Publikováno v:
Journal of medicinal chemistry. 64(15)
MyD88 gene mutation has been identified as one of the most prevalent driver mutations in the activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL). The published literature suggests that interleukin-1 receptor-associated kinase 1 (IRAK1) is